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TetraspaninAlthough cancers can be initially treated with the epidermal growth factor receptor (EGFR) inhibitor, geﬁti-
nib, continued geﬁtinib therapy does not beneﬁt the survival of patients due to acquired resistance through
EGFR mutations, c-MET ampliﬁcation, or epithelial–mesenchymal transition (EMT). It is of further interest to
determine whether mesenchymal-like, but not epithelial-like, cancer cells can become resistant to geﬁtinib
by bypassing EGFR signaling and acquiring alternative routes of proliferative and survival signaling. Here
we examined whether geﬁtinib resistance of cancer cells can be caused by transmembrane 4 L six family
member 5 (TM4SF5), which has been shown to induce EMT via cytosolic p27Kip1 stabilization. Geﬁtinib-
resistant cells exhibited higher and/or sustained TM4SF5 expression, cytosolic p27Kip1 stabilization, and mes-
enchymal phenotypes, compared with geﬁtinib-sensitive cells. Conversion of geﬁtinib-sensitive to -resistant
cells by introduction of the T790M EGFR mutation caused enhanced and sustained expression of TM4SF5,
phosphorylation of p27Kip1 Ser10 (responsible for cytosolic location), loss of E-cadherin from cell–cell con-
tacts, and geﬁtinib-resistant EGFR and survival signaling activities. Additionally, TM4SF5 overexpression less-
ened the sensitivity of NSCLC cells to geﬁtinib. Suppression of TM4SF5 or p27Kip1 in geﬁtinib-resistant cells
via the T790M EGFR mutation or TM4SF5 expression rendered them geﬁtinib-sensitive, displaying more
epithelial-like and less mesenchymal-like characteristics. Together, these results indicate that TM4SF5-
mediated EMT may have an important function in the geﬁtinib resistance of cancer cells.
© 2011 Elsevier B.V. All rights reserved.Introduction
Cancer cells can be initially treated with tyrosine kinase inhibitors
(TKIs), such as epidermal growth factor receptor (EGFR) inhibitor
geﬁtinib [1,2]. Most lung cancer patients with activating EGFR muta-
tions such as exon 19 deletion and the exon 21 L858R substitution
were signiﬁcantly sensitive to EGFR-TKIs [3]. However, continued
geﬁtinib therapy does not beneﬁt the survival of patients with
EGFR-sensitive mutations, due to acquired resistance caused by the
secondary mutations such as T790M in the EGFR kinase domain [4].
The T790M mutation occurs in approximately 50% of lung cancer
patients with mutant EGFR, causes steric hindrance to TKI binding
and enhances EGFR afﬁnity for ATP with competitively decreased
binding to geﬁtinib, an ATP-competitive kinase inhibitor [5,6]. Other
mutations of EGFR such as D761Y and L747S also lead to geﬁtinib re-
sistance during TKI therapy [7,8]. Among NSCLC, representatively
geﬁtinib-sensitive (with an IC50 less than 0.025 μM) HCC827 cellslege of Pharmacy, SeoulNational
public of Korea. Tel.: +82 2 880
l rights reserved.have a deletion mutation in EGFR (from E746 to A750 in exon 19),
whereas geﬁtinib-resistant (with an IC50 higher than 10 μM) NCI-
H1975 cells have mutations in EGFR of T790M (within exon 20) and
L858R (within exon 21) [9,10].
However, acquired resistance to geﬁtinib in NSCLC can also be at-
tributed to ampliﬁcation of c-MET, a gene that encodes a receptor
tyrosine kinase for hepatocyte growth factor [11]. A subpopulation
from geﬁtinib-sensitive NSCLC HCC827 cells (derived from the selec-
tion of resistant cells by culturing the cells to increasing geﬁtinib con-
centrations) demonstrates TKI resistance that maintains ErbB3/PI3K/
Akt pathway activation and c-MET ampliﬁcation, and inhibition of c-
MET restored the sensitivity to geﬁtinib [12]. A geﬁtinib-resistant
subpopulation of geﬁtinib-sensitive A549 cells shows activated PI3K
activity and IGF1R pathway and inhibition of IGFIR restored the sen-
sitivity to geﬁtinib [13]. Thus, bypassing EGFR signaling for cell
growth and proliferation appears to be another mechanism for geﬁti-
nib resistance.
Additionally, acquired TKI resistance of NSCLC appears to correlate
with epithelial–mesenchymal transition (EMT) that affects cell–cell
contacts [14]. TGFβ1-mediated EMT causes resistance to geﬁtinib in
addition to loss of E-cadherin and cytokeratin expression [15]. Thus,
mesenchymal-like, but not epithelial-like, NSCLC cells may likely be
515M.-S. Lee et al. / Biochimica et Biophysica Acta 1823 (2012) 514–523resistant to TKI inhibition such that mesenchymal-like cells bypass
EGFR signaling and acquire alternative routes of proliferative and sur-
vival signaling. For this to occur, membrane receptors may be cooper-
ative to specify the alternative signaling pathway(s) or organized to
allow synergistic or antagonistic relationships between them during
communications of cancer cells with diverse extracellular cues.
EMT enhances cell proliferation, migration, and invasion [16]. In
addition to the TGFβR and c-MET pathways, tetraspan TM4SF5 also
induces EMT with persistent proliferation even under conﬂuent con-
ditions [17] and accelerates S-phase entry [18]. TM4SF5 expression
decreases expressions of E-cadherin and ZO1, and increases expres-
sion of α-smooth muscle actin (α-SMA) leading to a loss of cell–cell
contacts, depending on cytosolic p27Kip1-mediated RhoA inactivation
and morphological changes; the TM4SF5-mediated EMT is blocked by
a suppression of TM4SF5 or p27Kip1 [17]. Even hepatocyte growth fac-
tor (HGF)-mediated EMT of endogenously TM4SF5-expressing hepa-
tocytes was also blocked by TM4SF5 suppression [17]. The tetraspan
TM4SF5 homologous to the lung cancer antigen L6 forms the trans-
membrane 4 L six family with L6, IL-TIMP, and L6D [19]. This family
shares four-membrane spanning membrane topology with genuine
TM4SF (transmembrane 4 superfamily) or tetraspanins [20]. TM4SFs
are known to regulate the integrity of a membrane receptor network,
known as a ‘tetraspanin-web’ or ‘tetraspanin-enriched microdomain
(TERM)’ where they collaboratively perform their biological function
[21]. TM4SF5 collaborates with integrins or growth factor receptors
for cellular function [22,23].
Thus, we rationalized that geﬁtinib-resistant cells may adapt an
alternative signaling pathway to bypass EGFR-dependent proliferation
and survival signaling pathways via integrative roles by (an)other
membrane receptors such as tetraspanins. In the current study, we ex-
plored whether TM4SF5 was involved in geﬁtinib resistance of cancer
cells, because TM4SF5 has been shown to induce EMT and collaborate
with other receptors on the cell membrane surface [22,23]. We exam-
ined the expression and activity levels of signaling molecules in
geﬁtinib-sensitive HCC827 and -resistant NCI-H1975 [9,10] cells to de-
terminewhether TM4SF5-mediated signaling and cellular function cor-
relate with resistance to geﬁtinib. We found that TM4SF5-mediated
effects, including cytosolic p27Kip1 stabilization and EMT, appeared to
be involved in geﬁtinib resistance of NSCLC cells.
Materials and methods
Cells
HCC827 (with EGFR mutation of deletion from E746 to A750),
NCI-H1975 (with EGFR mutation of L858R and T790M), NCI-H358
(with K-Ras mutation of G12C) lung carcinoma and MKN45 (with c-
MET ampliﬁcation) gastric adenocarcinoma cells (ATCC, Manassas,
Virginia) were maintained in RPMI-1640 with 10% FBS, 10 U/ml peni-
cillin, and 10 μg/ml streptomycin at 37 °C and 5% CO2. HCC827 cells
stably-expressing mock or T790M EGFR or FLAG-TM4SF5 were estab-
lished via transfection and G418 (500 μg/ml, A.G. Scientiﬁcs) selection
and maintained in RPMI-1640 containing 10% FBS and 250 μg/ml G418.
Standard Western blots
Cells were transiently transfected with shRNA against control se-
quence or TM4SF5 for 24 h, or infected with adenovirus encoding
for siRNA against control or p27Kip1 sequence [17] overnight, before
treatmentwith DMSO or geﬁtinib (LC Laboratories) for 24 h at different
concentrations. Cells were then harvested for whole cell lysates with
RIPA buffer (50 mM HEPES, pH 7.5, 0.1% SDS, 1% NP-40, 0.5% sodium
deoxycholate, 150 mM NaCl, 50 mM NaF, 1 mM Na2VO4, 1 mM nitro-
phenylphosphate, and protease inhibitors). The lysates were normal-
ized and processed for standard Western blots using antibody against
E-cadherin (#610182, BD Bioscience; sc-8426, Santa Cruz Biotech.),active EGFR (#610025), p27Kip1 (#610241, BD Transduct. Lab.),
pS10p27Kip1 (#AP3191a, ABGENT), β-catenin (sc-7963, Santa Cruz Bio-
tech.), pY1173EGFR (#4407), phospho-Y992EGFR (#2235), phospho-
Y845EGFR (#2231), phospho-Y1045EGFR (#2237), phospho-Y1068EGFR
(#2234), Erk1/2 (#9102, Cell Signaling), phospho-Erk1/2 (#9101s,
Cell Signaling), FLAG (#2368), phospho-S473Akt (#9272, Cell Signal-
ing), Akt (sc-7985R, Santa Cruz Biotech.), α-smooth muscle actin
(SMA, #A2547, Sigma), vimentin (#V5255, Sigma), α-tubulin
(#T5168, Sigma), EGFR (sc-03, Santa Cruz Biotech.), or TM4SF5 [17].
Cell imaging
Cells in normal culture media were imaged using a camera-
equipped CX41 microscopy (Olympus).
MTT assay
Cells (3000 cells/well) were seeded in 96 well plates and 24 h later
DMSO or geﬁtinib was added at different concentrations (0 to 10 μM)
for additional 72 h. Standard reading of MTT (Sigma) metabolites was
performed for OD540 and mean±standard deviation values were
graphed.
Coimmunoprecipitation
Whole cell lysates from stably FLAG-mock or FLAG-TM4SF5 expres-
sing HCC827 cells under a subconﬂuent normal culture condition were
incubated with anti-FLAG M2 sepharose beads (Sigma, 1 mg protein/
40 μl of 50% slurry/condition) overnight at 4 °C, washed twice with
lysis buffer, and then twice with cold PBS. Immunoprecipitates were
boiled within 2× SDS-PAGE sample buffer, and immunoblotted with
anti-FLAG M2 (#2368, Sigma) or -EGFR (sc-03, Santa Cruz Biotech.)
antibody.
Indirect immunoﬂuorescence
Cells were replated on ﬁbronectin (10 μg/ml)-precoated cover-
slips and incubated within normal serum-containing media overnight
at 37 °C. The cells were then treated with DMSO or 0.01 μM geﬁtinib
for additional 18 h, before immunostaining [17]. Antibodies for
immunostaining include anti-p27Kip1 (#610241, BD Transduction. Lab),
or E-cadherin (#610182, BD Biosource) antibody. DNA in nucleus was
stained by DAPI (Molecular Probes). Mounted samples were visualized
using a ﬂuorescent microscope (BX51, Olympus).
Results
Geﬁtinib-resistant NCI-H1975 cells efﬁciently grow in a scattered pattern
despite decreased EGFR signaling activity
While trying to understand the mechanisms underlying geﬁtinib
resistance of cancer cells, we hypothesized that resistance might be
caused by alternative signaling pathways emanating from membrane
receptors that closely collaborate with EGFR. To test this hypothesis,
we ﬁrst compared the characteristics of geﬁtinib-sensitive HCC827
and -resistant NCI-H1975 cells [9]. To ﬁrst conﬁrm their susceptibility
to geﬁtinib, we performed MTT assay using the cell lines treated
with vehicle or geﬁtinib at various concentrations (0 to 10 μM). As
expected, HCC827 cells were sensitive to geﬁtinib with an IC50 of ap-
proximately 0.02 μM, whereas NCI-H1975 cells were resistant with an
IC50≥10 μM (Fig. 1A). Immunoblotting for EGFR and survival signal-
ing molecules from subconﬂuent cells cultured under normal culture
conditions showed that HCC827 exhibited higher EGFR phosphoryla-
tion and activity than NCI-H1975 cells, whereas phosphorylation of
Akt and Erk1/2 was slightly higher in the NCI-H1975 cells (Fig. 1B,
middle). NCI-H1975 cells were more efﬁciently proliferative under
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Fig.1. Geﬁtinib-resistant NCI-H1975 cells efﬁciently grow in a scattered pattern despite decreased EGFR signaling activity. (A) Geﬁtinib-sensitive HCC827 and -resistant NCI-H1975
cells were analyzed for survival in the presence of treatment with geﬁtinib at different concentrations (0 to 10 μM) via MTT assay. Each value was averaged from hexaplicate in one
experiment of 3 independent MTT assay (i.e., hexaplicate×3 times). (B) The subconﬂuent cells were harvested and processed for standard Western blots for the indicated mole-
cules. (C) Proliferations of the cells in the normal culture media were examined by determination of cell numbers at different times after cell seeding at the same number.
(D) Phase-contrast images were saved at a subconﬂuent condition within the normal culture media. (E) Cells were seeded onto normal culture media-precoated cover glasses
for 24 h and then immunostained for E-cadherin or vimentin, as explained in the Materials and Methods. Scale bar; 20 μm. The data shown are representative from 3 independent
experiments.
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This pro-proliferative phenotype of NCI-H1975 cells indicates that
alternative EGFR-bypassing signaling pathway(s) may still be promi-
nent. Additionally, NCI-H1975 cells grew in a scattered pattern
whereas HCC827 cells grew in colonies (Fig. 1D). We also checked the
expression level of TM4SF5 because of its pro-proliferative function
[24] and role in EMT [17]. NCI-H1975 cells with a higher TM4SF5 ex-
pression showed a less E-cadherin (an epithelial marker) expression
but more α-SMA and vimentin (mesenchymal markers) expressions,
compared with HCC827 cells expressing a lower TM4SF5 level(Fig. 1B, bottom); thus, highly expressed TM4SF5 might presumably
cause a scattered-growth pattern (Fig. 1D). Being consistent, HCC827
cells growing in a cobblestone pattern well-established cell–cell adhe-
sions with E-cadherin at the cell–cell contact sites but showed a less
vimentin expression, whereas NCI-H1975 cells growing in a scattered
pattern showed less signiﬁcant cell–cell adhesions with a lower E-
cadherin expression and amore vimentin expression (Fig. 1E). Interest-
ingly, both HCC827 and NCI-H1975 cell lines were not homogeneous
with regards to E-cadherin and vimentin expressions; cell–cell contacts
betweenHCC827 cells thus showedmore E-cadherin in certain contacts
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Fig. 2. Survival of geﬁtinib resistant cells in the presence of geﬁtinib correlated with sustained TM4SF5 expression. (A and B) Subconﬂuent geﬁtinib-sensitive HCC827 and -resistant
NCI-H1975, MKN45, and H358 cells were grown with or without geﬁtinib at different concentrations for 24 h before preparation of whole cell lysates. (C) Whole cell lysates from
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showed more vimentin in certain cells but less in other cells (Fig. 1E,
bottom and right). Together, these results suggest that NCI-H1975
cells have certain growth and survival signaling activities presumably
via TM4SF5 that are sufﬁcient to alternatively bypass the EGFR signaling
pathway, where a higher relative level of TM4SF5 to EGFR expression in
NCI-H1975 cells was correlative with a less dependence on EGF signal-
ing, compared with HCC827 cells, although cells might have heteroge-
neous EGFR and TM4SF5 expression levels.
Survival of geﬁtinib resistant cells in the presence of geﬁtinib correlated
with sustained TM4SF5 expression
Further, the cells resistant to geﬁtinib due to an active mutation
(G12C) in K-Ras (NCI-H358 cells) or ampliﬁcation of c-MET (MKN45
cells) showed values of IC50 against geﬁtinib higher than 10 μM
(data not shown) and also showed higher and/or sustained expres-
sions of TM4SF5 in the presence of geﬁtinib treatment, compared to
geﬁtinib-sensitive HCC827 cells (Fig. 2A and B). Interestingly, EGFR
inhibition in geﬁtinib-sensitive HCC827 cells caused a reduced
TM4SF5 expression (Fig. 2A and B), which may be explained by the
observations that TM4SF5 induction involves a cross-talk between
TGFβ1 and EGFR signaling pathways and inhibition of EGFR activity
abolishes the TM4SF5 expression (M. Kang and J.W. Lee, unpublished
data). This correlation between geﬁtinib resistance and sustained
TM4SF5 expression may indicate a close functional relationship be-
tween EGFR and TM4SF5. Such an indication may also be supportedby a concept that TM4SF5 as a tetraspan(in) or TM4SFs can function
in regulation of membrane receptor integrity on cell surface [25].
Thus, we next examined whether a physical linkage between EGFR
and TM4SF5 exists. From HCC827 cells stably-transfected with
FLAG-mock or FLAG-TM4SF5 plasmid, EGFR was coimmunoprecipi-
tated with FLAG-TM4SF5 and vice versa (Fig. 2B). Together, these ob-
servations indicate that TM4SF5 may play roles in the signaling for
sufﬁcient growth of the geﬁtinib-resistant cells, alternatively bypass-
ing the EGFR signaling pathway.Sustained EGFR, Erk, and Akt signaling activities in geﬁtinib-resistant
cells after geﬁtinib treatment correlated with TM4SF5-mediated effects,
including cytosolic p27Kip1 stabilization
When cells were treated with geﬁtinib at different concentrations
from 0 to 1.0 μM, phosphorylation of EGFR, Akt, and Erk1/2 in
geﬁtinib-resistant NCI-H1975 cells was sustained, whereas their
basally-robust phosphorylation in geﬁtinib-sensitive HCC827 cells
was dramatically reduced (Fig. 3A), as shown previously [4]. We
thus tried to test whether such a differential response to geﬁtinib be-
tween HCC827 and NCI-H1975 cells might also correlate with higher
and/or sustained TM4SF5 expression. Sustained TM4SF5-expression
correlated with a different pattern of signaling activities between
both cell lines treated with geﬁtinib: TM4SF5 levels in NCI-H1975
cells were highly sustained even with geﬁtinib treatment whereas
TM4SF5 levels in HCC827 cells were reduced (Fig. 3A, bottom).
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zation of p27Kip1 in the cytosol during TM4SF5-mediated EMT, multi-
layer growth [17], and acceleration of G1- to S-phase entry [18].
Therefore, cytosolic p27Kip1 appears to play pro-tumorigenic roles in
cell proliferation and migration. We thus examined the localization
and expression of p27Kip1 in HCC827 and NCI-H1975 cells in the absence
or presence of geﬁtinib. Without geﬁtinib treatment, HCC827 cells
showed p27Kip1 expression mostly in the nucleus whereas NCI-H1975
cells clearly demonstrated cytosolic p27Kip1 (Fig. 3B, top). With geﬁtinib
treatment, HCC827 cells exhibitedmore enhanced p27Kip1 in the nucleus,
suggestive of the geﬁtinib-mediated cell growth arrest and death.
However, NCI-H1975 cells still showed cytosolic p27Kip1 stabilization
(Fig. 3B, bottom), indicating that TM4SF5 in NCI-H1975 cells might
play tumorigenic roles even in the presence of geﬁtinib (Fig. 3B,
bottom).
T790M EGFR mutation-mediated geﬁtinib resistance correlated with
sustained TM4SF5 expression and EMT process
The T790M EGFR mutation renders geﬁtinib resistance [3]. There-
fore, we investigated whether T790M EGFR introduction into HCC827
cells (already with EGFR mutation of deletion from E746 to A750)
caused cells to concomitantly become geﬁtinib-resistant and display
TM4SF5-mediated phenotypes. When the MTT assay was performed
with HCC827 stable transfectants (mock and T790M EGFR clones
1–5 and 2–1) and NCI-H1975 cells in the presence of geﬁtinib treat-
ment at different concentrations for 72 h, HCC827-T790M clones
and NCI-H1975 cells clearly showed resistance to geﬁtinib, although
HCC827 mock cells were sensitive (Fig. 4A). HCC827-T790M clones
enhanced and sustained the phosphorylation of EGFR (Supplementary
Fig. S1), and Akt after geﬁtinib treatment (Fig. 4B). Unlike HCC827
mock cells growing in a pattern of cobble stones, HCC827-T790M cells
grew in a scattered pattern (Fig. 4C). HCC827-T790M cells also in-
creased α-SMA (a mesenchymal marker) and decreased E-cadherin(an epithelial marker) expression, indicating an EMT by T790M EGFR
introduction, which were accompanied with enhanced and sustained
TM4SF5 expression in the presence of geﬁtinib treatment (Fig. 4D).
T790M EGFR transfection-mediated growth pattern in a scattering pat-
tern was correlated with the loss of E-cadherin from cell–cell contacts
and more p27Kip1 in the cytosol compared with mock-transfectants
(Fig. 4E). These observations using HCC827-T790M clones may suggest
that TM4SF5 is involved in geﬁtinib resistance that is associated with
the T790M EGFRmutation.
TM4SF5 overexpression rendered geﬁtinib-sensitive cells to be
geﬁtinib-resistant cells with EMT phenotypes
To reveal whether enhanced and/or sustained TM4SF5 expression
causes geﬁtinib-resistance, we overexpressed TM4SF5 in HCC827
cells and examined whether the stable HCC827-TM4SF5 transfectants
might become resistant against geﬁtinib, using the MTT assay. When
cells were treated with geﬁtinib at different (0 to 10 μM) concentra-
tions, TM4SF5-overexpressing HCC827 clones showed less sensitivity
to geﬁtinib than did HCC 827 mock cells, although they were less re-
sistant than HCC827-T790M2–1 cells (Fig. 5A). At 0.01 μM geﬁtinib
treatment, all TM4SF5-positive clones were signiﬁcantly (p≤0.05)
geﬁtinib-resistant differently from geﬁtinib-sensitive HCC827 cells,
whereas at a higher 0.1 μM, HCC827-TM4SF52–8 was insigniﬁcantly
geﬁtinib-resistant, similar to HCC827 cells (Fig. 5A). This observation
indicates that the TM4SF5 expression may not be all requirements for
the geﬁtinib resistance. Additionally, the HCC827-TM4SF5 clones not
only enhanced and sustained EGFR and Akt phosphorylation but also
enhanced TM4SF5 expression and p27Kip1 Ser10 phosphorylation,
which is known to cause its cytosolic localization [17], although
their levels were slightly differential between clones (Fig. 5B). Indeed,
compared with HCC827 cells, HCC827-TM4SF5 cells clearly showed
cytosolic localization of p27Kip1 under basal and geﬁtinib-treated con-
ditions (Fig. 5C). HCC827-TM4SF5 cells also grew in a scattered
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sion (i.e., vimentin and α-SMA) and decreased an epithelial marker ex-
pression (E-cadherin; Fig. 5E), again indicating that geﬁtinib-resistant
HCC827-TM4SF5 cells underwent EMT.
Geﬁtinib resistance was reduced via suppression of TM4SF5 or p27Kip1
TM4SF5 expression stabilizes cytosolic p27Kip1 through enhanced
stabilities of its mRNA and protein, and is correlated with the EMT pro-
cess [17]. Therefore, we next examinedwhether suppression of TM4SF5
or p27Kip1 would revert geﬁtinib resistance of HCC827-T790M2–1 or
HCC827-TM4SF5 cells. TM4SF5 suppression reduced Akt phosphoryla-
tion (pS473Akt) and reduced mesenchymal-like characteristics via
increased E-cadherin but reduced α-SMA levels (Fig. 6A). Although
basal p27Kip1 was slightly increased presumably due to cytotoxicity,
Ser10 phosphorylated p27Kip1 (i.e., cytosolic p27Kip1) decreased on
TM4SF5 suppression, compared with control shRNA-transfection(Fig. 6A). It is thus likely that TM4SF5 suppression might block the
TM4SF5-mediated effects on cytosolic p27Kip1 stabilization and EMT
and consequently geﬁtinib resistance. Meanwhile, when HCC827-
T790M2–1 cells were infected with adenovirus expressing small inter-
fering RNA (siRNA) against a control scrambled sequence or p27Kip1.
Suppression of p27Kip1 in HCC827-T790M2–1 cells decreased
pY1068EGFR and pS473Akt and enhanced the expression of E-cadherin
and β-catenin under both basal and geﬁtinib-treated conditions, indi-
cating that mesenchymal characteristics of HCC827-T790M2–1 cells
were changed to epithelial characteristics after p27Kip1 suppression
(Fig. 6B). Although HCC827-T790M2–1 cells were still more geﬁtinib-
resistant compared with the HCC827-T790M2–1 cells with a suppressed
TM4SF5 or p27Kip1 level, the cells showed a certain inhibition of EGFR by
geﬁtinib (Fig. 6A and B), presumably because the exogenous T790M
EGFR expression level of HCC827-T790M2–1 cellsmight not be dominant
over the endogenous EGFR level. Alternatively, it may be likely that
HCC827-T790M2–1 cells did not accompany the primary EGFRmutation
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Fig. 6. Geﬁtinib resistance was reduced via suppression of TM4SF5 or p27Kip1. HCC827 cells stably transfected with T790M EGFR (A and B) or with TM4SF5 (C) were transiently
transfected with shRNA against control sequence or TM4SF5 (A) or infected with adenovirus expressing siRNA against control sequence or p27Kip1 [17] overnight (B and C) and
then treated with DMSO (−) or 0.01 μM geﬁtinib (+) for 24 h. Whole cell lysates were prepared, normalized and processed to standard Western blots for the indicated molecules.
Data shown represent 3 isolated experiments.
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ﬁnity to ATP would not be available to cause an efﬁcient blocking of
ATP-competitive kinase inhibitor, geﬁtinib [6]. Being correlated, the
p27Kip1-suppressed cells reduced pS473Akt under basal conditions and
further decreased pS473Akt after geﬁtinib treatment compared with
non-suppressed cells, indicating that p27Kip1 suppression enhanced
susceptibility to geﬁtinib treatment (Fig. 6B). Such a reversion from
geﬁtinib-resistant to -sensitive cells via suppression of p27Kip1 also oc-
curred in HCC827 cells overexpressing TM4SF5 (HCC827-TM4SF52–3),
which decreased α-SMA, pY1068EGFR, and pS473Akt but increased β-
catenin after p27Kip1 suppression (Fig. 6C).
Discussion
In the present study, we observed that geﬁtinib resistance in cancer
cells could result from expression of TM4SF5, leading to EMT, at least
through cytosolic p27Kip1 stabilization. So far evidence exists that geﬁ-
tinib resistance of cancer cells is attributed to acquired mutations in
EGFR (e.g., T790M) during TKI therapy that cause steric hindrance to
geﬁtinib and enhance the afﬁnity of mutated EGFR for ATP, thus lower-
ing the afﬁnity for geﬁtinib [5] to nullify the hypersensitivity of activat-
ing EGFRmutations [6]. T790Mmutation-mediated geﬁtinib resistance
accounts for 50% of TKI resistance in patients carrying an EGFR muta-
tion [6]. The resistance has also been attributed to the contribution of
other membrane receptors or their downstream effector(s). Geﬁtinib
resistance of A549 cells is caused by PI3K activation and IGF1R pathway
[13], which are suggested to be alternative pathways for proliferation
that bypass the EGFR signaling pathway [6]. Additionally, PI3K/Akt ac-
tivity and c-MET ampliﬁcation, which accounts for 20% of TKI-resistant
tumors [6], also result in geﬁtinib resistance of NSCLC [12]. However, c-
MET is well-known to cause cell scattering and EMT as a receptor for
hepatocyte growth factor [26]. Furthermore, loss of molecules at cell–Fig. 5. TM4SF5 overexpression rendered geﬁtinib-sensitive cells to be geﬁtinib-resistant cells
TM4SF5 plasmids were analyzed by MTT assay for cell survival with DMSO (0) or geﬁtinib tr
iment of 3 independent MTT assay (i.e., hexaplicate×3 times). (B, C, and E) Subconﬂuent HC
(+) for 24 h and then harvested for standardWestern blots for the indicated molecules (B an
staining (of nuclear DNA) and indirect immunoﬂuorescence using anti-p27Kip1 (green) ant
microscope or seeded onto the normal culture media-precoated cover glasses for 24 h an
methods section. Scale bar; 20 μm. Data shown represent 3 independent experiments.cell contacts has recently been reported to be a possible determinant
of sensitivity of NSCLC cells and xenografts against erlotinib, another
EGFR kinase inhibitor [14]. Interestingly, as shown in the present
study, TM4SF5, as a membrane protein that induces EMT [17,19],
causes geﬁtinib resistance, and geﬁtinib-resistant cells with the
T790M EGFR mutation (i.e., NCI-H1975 cells) showed enhanced ex-
pression of α-SMA and TM4SF5 as well. Stable transfection of
T790M EGFR into HCC827 cells led to geﬁtinib resistance, enhanced
TM4SF5 expression, and was correlated with EMT because the stable
transfectants demonstrated enhanced expression of mesenchymal
markers (i.e., vimentin and α-SMA) but reduced epithelial marker
(i.e., E-cadherin).
Stabilization of p27Kip1 in the cytosol has been shown in diverse
tumor tissues [27], and accounts for inactivation of RhoA GTPase via
direct interaction, resulting in regulation of actin dynamics and cell
migration [28,29]. TM4SF5 expression causes cytosolic p27Kip1 stabili-
zation, and EMT with loss of E-cadherin expression, while suppression
of TM4SF5 or p27Kip1 recovers E-cadherin expression at cell–cell con-
tacts [17]. Additionally, suppression of p27Kip1 results in a delay of
TM4SF5-accelerated G1- to S-phase entry [18]. Interestingly, cytosolic
p27Kip1 might also be involved in geﬁtinib resistance of NSCLC that is
mediated by TM4SF5 or T790M EGFR expression, because suppression
of p27Kip1 in geﬁtinib-resistant cells rendered these cells to be geﬁtinib-
sensitive. Therefore, cytosolic p27Kip1 appears to be tumorigenic by
being involved in TM4SF5-mediated EMT, although nuclear p27Kip1
can be anti-tumorigenic as a cyclin-dependent kinase inhibitor [30].
In addition to being related to EMT, TM4SF5 as a tetraspan(in)
traversing the membrane four times may presumably locate to the
tetraspan(in)-enriched microdomain (TERM) of the cell plasma mem-
brane, playing roles in organizing the integrity ofmembrane receptors in-
cluding integrins and growth factor receptors through massive protein–
protein interactions [21,31,32]. Integrin α5 binds to TM4SF5 and iswith EMT phenotypes. (A) HCC827 cells stably-transfected with mock, T790M EGFR, or
eatment from 0.001 to 10 μM. Each value was averaged from hexaplicate in one exper-
C827-mock or -TM4SF5 stable clones were treated with DMSO (−) or 0.01 μM geﬁtinib
d E), or reseeded on ﬁbronectin (10 μg/ml) -precoated coverglasses for 2 h before DAPI
ibody (C). Scale bars depict 20 μm. (D) The cells were imaged using a phase-contrast
d then immunostained for E-cadherin or vimentin, as explained in the Materials and
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TM4SF5, comparedwith the surface of cells lacking TM4SF5 [22]. Similar-
ly, CD63 and CD82 aremore likely to be found on the surface of cells that
overexpress L6-Ag [33], which is anothermember of the transmembrane
4 L six family [20]. Thus, it cannot be ruled out that IGF1R, a player in TKI
resistance [13], may also be susceptible to TM4SF5- or tetraspan(in)-me-
diated organization of receptor networks on the cell surface. TM4SF5-
mediated regulation of membrane receptor networks on the cell surface
may also lead to the geﬁtinib resistance. In the present study, we ob-
served that geﬁtinib-sensitive cells showed a higher basal EGFR activity,
compared with geﬁtinib-resistant cells. However, the EGFR activity of
geﬁtinib-sensitive cells was dramatically reduced after geﬁtinib treat-
ment, whereas the EGFR activity of resistant cells was more persistent
(similar to the basal level) even after geﬁtinib treatment. Therefore,
such persistent EGFR activity of resistant cells after geﬁtinib treatment
might result from effective retention of EGFR on the cell surface via a
physical linkage between TM4SF5 and EGFR. Indeed, in the present
study, we have observed that geﬁtinib-resistant cells showed a coimmu-
noprecipitation between the both receptors. Therefore, TM4SF5-
mediated effects, including EMT and membrane retention of EGFR via
protein interactions, may be involved in geﬁtinib resistance of cancer
cells.
In epithelial cells, TM4SF5 is shown to interactwith integrinsα2 orα5
during migration or angiogenesis, respectively [22,23]. In Cos7 ﬁbro-
blasts, TM4SF5 regulates actin remodeling and focal adhesion dynamics
through an interaction with integrin α2, which is negatively controlled
by serum treatment [34]. It is thus likely that cross-talks between
TM4SF5 and other membrane receptors such as integrins and/or growth
factor receptor are involved in the regulation of diverse cellular functions,
including cell–cell adhesions. It is suggested that different TERM constit-
uents may lead to diverse membrane properties such as signaling, cyto-
skeletal connection, and/or curvatures for different cellular functions
[35]. In addition to TM4SF5 [16,17], another tetraspanin, CD151 is also
shown to induce EMT via a signaling through integrin α6β1 and PI3K
[36]. Growth factor receptors or receptor tyrosine kinases, such as c-
MET is also well-connected with EMT [37]. Furthermore, attenuation of
EGFR signaling (activity) is obviously correlated with mesenchymal cell
features [38]. Therefore, depending on roles of tetraspanins through
massive protein–protein interactions at TERMs, tetraspanins may
be involved in regulation of growth factor receptor activity and con-
comitantly of cell–cell adhesions.
During TKI therapy, the acquired T790Mmutation in EGFR accounts
for amajor TKI resistancemechanism [6]. In the current study,we found
that introduction of T790M EGFR into geﬁtinib-sensitive NSCLC cells
also resulted in geﬁtinib resistance and TM4SF5 overexpression. Fur-
thermore, overexpression of TM4SF5 in geﬁtinib-sensitive cancer cells
resulted in geﬁtinib resistance, although it occurred at a resistance
level less than that of the T790M EGFR mutation, probably indicating
that more than TM4SF5 might be involved in geﬁtinib resistance. Such
TM4SF5 overexpression-mediated resistance to geﬁtinib appeared not
to involve the secondary acquired EGFRmutation at T790 or other resi-
dues, because resistant cells via TM4SF5 overexpression did not show
any acquired EGFR mutation within exons 18, 19, 20, and 21 (Supple-
mentary Fig. S2). Therefore, TM4SF5 may transduce an alternative
signaling pathway that bypass the EGFR signaling pathway, accounting
for anothermajor portion of geﬁtinib resistance in lung cancer irrelevant
to acquired EGFR mutation(s) of T790M. Interestingly, the geﬁtinib-
resistant cells alternatively due to c-MET ampliﬁcation (MKN45 cells)
or K-Ras activation (NCI-H358 cells) also showed higher expression
levels of TM4SF5, compared to geﬁtinib-sensitive HCC827 cells. It may
thus be likely because TM4SF5 can possibly be involved both in EMT-
mediated and in EGFR-bypassing signaling-mediated resistance against
geﬁtinib. Being consistent, TM4SF5 overexpression accelerates cell cycle
progression fromG1 phase to S phase [18], suggesting that TM4SF5may
efﬁciently stimulate a cell growth-stimulatory signaling even in the con-
dition where EGFR signaling may be less functional.Conclusions
TM4SF5-mediated EMT and regulation of activity or integrity of
membrane receptors including EGFR, IGF1R, and/or c-MET on the
cell surface, may likely be important for geﬁtinib resistance of cancer
cells. It may thus be interesting to examine whether geﬁtinib-
resistant lung cancer patients overexpress TM4SF5, compared with
geﬁtinib-sensitive patients, to get the idea whether anti-TM4SF5 re-
agent [39] may be a therapeutic reagent against geﬁtinib-resistant
lung cancer patients.
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